Search Results for brca

Research News

Niraparib Receives FDA Approval as First-Line Maintenance Therapy for Advanced Ovarian Cancer

(May 4, 2020) On April 29th, the Food and Drug Administration approved niraparib (Zejula, GlaxoSmithKline) as a first-line maintenance treatment for advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer, regardless of BRCA mutation status. Niraparib was first approved by the FDA for treatment of recurrent ovarian cancer in 2017. This most recent approval means ovarian cancer patients do not need to have experienced a recurrence to receive the drug…

Up close science photo of a droplet hovering over a beaker

SGO 2020 Highlights

(April 17, 2020) The Society of Gynecologic Oncology's Annual Meeting on Women's Cancer brings together women's healthcare professionals from across the globe to discuss the latest findings in gynecologic oncology.  This year, the conference is being held virtually, through a series of high-level webinars that are free and open to the public. Click through to register with the "Registration Link for Non-CE" option…

Jane Rubin by Lake

Writing for Her Life | OCRA Heroes

Jane Rubin speaks quickly, with sentences not so much ending but flowing seamlessly into new thoughts and directions. Listening to her talk about her life and her work is like listening to someone try to cram an epic novel into a paragraph. Her interests and hunger for learning know no bounds.  Jane, a 20-year breast cancer survivor…

Breastfeeding

Update to Benefits of Breastfeeding Against Ovarian Cancer

(April 7, 2020) In a study published last week in the oncology Journal of the American Medical Association, breastfeeding was found to be a factor for reduced risk of developing invasive ovarian cancer. Researchers collected information on close to 10,000 women with ovarian cancer, and found that breastfeeding was associated with a "24% lower risk of invasive ovarian cancer." As stated in the abstract…

science lab closeup

Statins Present New Directions for Ovarian Cancer Research

(3/17/2020) Research out of the University of Bristol looked at genes and how they inhibit an enzyme involved in regulating the body’s cholesterol. This enzyme is the target of statin drugs, which are prescribed to lower cholesterol levels. The study involved 63,347 women between 20 and 100 years old, of whom 22,406 had ovarian cancer. An additional 31,448 women who carried the BRCA1/2 fault…

Blazing New Trails | Meet a Scientist

She has swum in the Amazon, gone ice fishing in the Arctic, traveled the Galapagos, and hang-glided in New Zealand. But the biggest trail Dr. Beth Karlan has blazed throughout her life has been in the field of gynecologic oncology. Dr. Karlan is Professor and Vice Chair of Women’s Health Research in the Department of Obstetrics and Gynecology at the David Geffen School of Medicine…

Dr. Ugo Cavallaro

OCRA Awards $6.6 Million in Ovarian Cancer Research Grants for 2020

(January 13, 2020) Thanks to your support, 22 top scientists at 19 eminent medical centers across the world will delve into important topics across the ovarian cancer landscape. In 2020, along with our other ongoing grants and programs, OCRA is investing nearly $9 million in the fight against ovarian cancer. These grants, awarded internationally for the first time in OCRA's history…

Phase II Trial of Gemcitabine+ATR Inhibitor: Translational Studies

Ovarian cancer (EOC) remains the most lethal gynecologic malignancy, of which high grade serous EOC (HGSOC) represents 70% of cases.  Current standard of care treatment with platinum-based chemotherapy results in complete remissions in >70% of EOC patients, however relapse occurs in >90% of those responders.  Those with platinum-resistant EOC (PROC) have limited therapeutic options, typically single agent chemotherapies with or without bevacizumab…

Targeting ER Stress Pathway in CARM1-Expressing Ovarian Cancer

Epithelial ovarian cancer (EOC) remains the deadliest gynecological cancer in the United States. EOC is comprised of multiple separate diseases. High grade serous ovarian carcinoma (HGSOC) is the most common subtype (>70% of EOC cases) and accounts for the majority of EOC-associated deaths. To this day, there is no effective single therapy that has proven beneficial for all EOC patients…

Jianhuang Lin, PhD

Dr. Jianhuang Lin is currently a Postdoctoral Fellow in the laboratory of Dr. Rugang Zhang at The Wistar Institute, Philadelphia. Dr. Lin received in 2011 a Bachelor’s degree in Bioengineering from Fuzhou University, Fuzhou, Fujian, China, and he obtained his Ph.D. degree from the University of Tsukuba, Japan in 2017. At the University of Tsukuba, Dr…

scientist using microscope

Combination Niraparib plus Pembrolizumab Shows Promise

(June 18, 2019) Results of new trials, funded in part by OCRA though the Ovarian Cancer Dream Team and published in JAMA Oncology, show that combination niraparib plus pembrolizumab therapy showed promising antitumor activity in patients with ovarian cancer. Patients with recurrent ovarian carcinoma frequently develop resistance to platinum-based chemotherapy, at which time treatment options become limited…

ASCO Annual Meeting 2019

Highlights from American Society of Clinical Oncology’s Annual Meeting

OCRA is back from the American Society of Clinical Oncology’s annual meeting in Chicago, where doctors and researchers met to discuss the latest in the care of women with ovarian cancer. A few highlights: Affordable Care Act facilitates earlier diagnosis and treatment of ovarian cancer Medicaid expansion narrows racial gaps in access to timely ovarian cancer care Single-agent carboplatin not a good choice for elderly ovarian cancer patients Evaluating Olaparib for BRCA Wild-Type Platinum-Resistant Ovarian Cancer Benefit of Olaparib vs Chemo in Platinum-Sensitive Relapsed Ovarian Cancer Niraparib plus bevacizumab significantly improves PFS in platinum-sensitive recurrent ovarian cancer Progress is being made in the fight against ovarian cancer…